Corebridge Financial’s BridgeBio Pharma BBIO Stock Holding History

Corebridge Financial’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-68,866	Closed	-$2.38M	–	315
2025 Q1	$2.38M	Sell	68,866 -1,021	-1%	-$34.4K	0.01%	920
2024 Q4	$1.92M	Sell	69,887 -5,275	-7%	-$136K	0.01%	1035
2024 Q3	$1.91M	Sell	75,162 -463	-0.6%	-$12.2K	0.01%	1064
2024 Q2	$1.92M	Buy	+75,625	New	+$2.07M	0.01%	1017

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Corebridge Financial's BBIO Position: Q2 2025 in Review

Corebridge Financial sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 68,866 shares — an estimated $2.38M sold.

Corebridge Financial first reported a position in BBIO in Q2 2024 and held it in 4 quarters. The position peaked at $2.38M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Corebridge Financial reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 68,866 BridgeBio Pharma shares in Q2 2025, an estimated $2.38M.
Corebridge Financial first reported a position in BridgeBio Pharma in Q2 2024 and held it in 4 quarters.
Corebridge Financial's BridgeBio Pharma position peaked at $2.38M in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.